Skip to content

Pharminent

cropped-neurology_aaic_banner_frontpage_2026-07-15-1.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • M&A / Deals
  • Lilly, BMS, Incyte strike deals to keep biopharma’s AI integration rolling
  • M&A / Deals

Lilly, BMS, Incyte strike deals to keep biopharma’s AI integration rolling

BioSpace

A trifecta of newly inked tech partnerships--from Eli Lilly, Bristol Myers Squibb and Incyte--exemplify the increasingly central role that AI is playing in drug development.

Read full story

pharminent May 21, 2026 (Last updated: May 21, 2026)

BioSpace

A trifecta of newly inked tech partnerships–from Eli Lilly, Bristol Myers Squibb and Incyte–exemplify the increasingly central role that AI is playing in drug development.

Read full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: BioMarin bounces back as Voxzogo performs ‘bigger than expected’ in new indication
Next: Lilly’s ‘triple G’ retatrutide aces crucial obesity trial

Related Stories

  • M&A / Deals

J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout

pharminent July 31, 2026
  • M&A / Deals

Eisai and CORE Biomedicine agree on global licence for oncology pipeline

pharminent July 29, 2026
  • M&A / Deals

Argenx signs agreement to buy Forte Biosciences for $2.2bn

pharminent July 28, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.